Nubeqa (darolutamide)
Prostate cancer
ApprovedCommercial
Key Facts
About Bayer
Bayer AG is one of the world's largest pharmaceutical and life sciences companies, headquartered in Leverkusen, Germany. The company develops and commercializes innovative therapies across oncology, cardiology, ophthalmology, and hematology, while also maintaining leading positions in consumer health products and agricultural sciences. With operations in over 100 countries and approximately 100,000 employees globally, Bayer continues to focus on breakthrough innovations in health and nutrition.
View full company profileTherapeutic Areas
Other Prostate cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Erleada (apalutamide) | Johnson & Johnson | Approved |
| Xtandi (enzalutamide) | Astellas Pharma | Approved |
| Proxalutamide (HS-10370) | Hansoh Pharma | Phase 3 |
| Darolutamide (Nubeqa) | Orion Corporation | Approved |
| Relacorilant + Enzalutamide | Corcept Therapeutics | Phase 2 |
| NBTXR3 | Nanobiotix | Phase 1/2 |
| Praluzatamab ravtansine (CX-2009) | CytomX Therapeutics | Phase 1/2 |
| Bavdegalutamide (ARV-110) | Arvinas | Phase 2 |
| ARV-766 | Arvinas | Phase 2 |
| Alpha DaRT | Alpha Tau Medical | Phase 1/2 |
| Prognostic Genomic Tests | Eurobio Scientific | Commercial |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |